Menu
Currency
GWAS Study

A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25.

Hung RJ, McKay JD, Gaborieau V et al.

18385738 PubMed ID
GWAS Study Type
11713 Participants
51 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

HR
Hung RJ
MJ
McKay JD
GV
Gaborieau V
BP
Boffetta P
HM
Hashibe M
ZD
Zaridze D
MA
Mukeria A
SN
Szeszenia-Dabrowska N
LJ
Lissowska J
RP
Rudnai P
FE
Fabianova E
MD
Mates D
BV
Bencko V
FL
Foretova L
JV
Janout V
CC
Chen C
GG
Goodman G
FJ
Field JK
LT
Liloglou T
XG
Xinarianos G
CA
Cassidy A
MJ
McLaughlin J
LG
Liu G
NS
Narod S
KH
Krokan HE
SF
Skorpen F
EM
Elvestad MB
HK
Hveem K
VL
Vatten L
LJ
Linseisen J
CF
Clavel-Chapelon F
VP
Vineis P
BH
Bueno-de-Mesquita HB
LE
Lund E
MC
Martinez C
BS
Bingham S
RT
Rasmuson T
HP
Hainaut P
RE
Riboli E
AW
Ahrens W
BS
Benhamou S
LP
Lagiou P
TD
Trichopoulos D
HI
Holcátová I
MF
Merletti F
KK
Kjaerheim K
AA
Agudo A
MG
Macfarlane G
TR
Talamini R
SL
Simonato L
LR
Lowry R
CD
Conway DI
ZA
Znaor A
HC
Healy C
ZD
Zelenika D
BA
Boland A
DM
Delepine M
FM
Foglio M
LD
Lechner D
MF
Matsuda F
BH
Blanche H
GI
Gut I
HS
Heath S
LM
Lathrop M
BP
Brennan P
Chapter II

Abstract

Summary of the research findings

Lung cancer is the most common cause of cancer death worldwide, with over one million cases annually. To identify genetic factors that modify disease risk, we conducted a genome-wide association study by analysing 317,139 single-nucleotide polymorphisms in 1,989 lung cancer cases and 2,625 controls from six central European countries. We identified a locus in chromosome region 15q25 that was strongly associated with lung cancer (P = 9 x 10(-10)). This locus was replicated in five separate lung cancer studies comprising an additional 2,513 lung cancer cases and 4,752 controls (P = 5 x 10(-20) overall), and it was found to account for 14% (attributable risk) of lung cancer cases. Statistically similar risks were observed irrespective of smoking status or propensity to smoke tobacco. The association region contains several genes, including three that encode nicotinic acetylcholine receptor subunits (CHRNA5, CHRNA3 and CHRNB4). Such subunits are expressed in neurons and other tissues, in particular alveolar epithelial cells, pulmonary neuroendocrine cells and lung cancer cell lines, and they bind to N'-nitrosonornicotine and potential lung carcinogens. A non-synonymous variant of CHRNA5 that induces an amino acid substitution (D398N) at a highly conserved site in the second intracellular loop of the protein is among the markers with the strongest disease associations. Our results provide compelling evidence of a locus at 15q25 predisposing to lung cancer, and reinforce interest in nicotinic acetylcholine receptors as potential disease candidates and chemopreventative targets.

1,926 European ance other ancestry cases, 2,522 European and other ancestry controls

Chapter III

Study Statistics

Key metrics and study information

11713
Total Participants
GWAS
Study Type
Yes
Replicated
332 European ancestry cases, 462 European ancestry controls, 2,181 European and other ancestry cases, 4,290 European and other ancestry controls
Replication Participants
European, Other, European
Ancestry
Sweden, Czech Republic, Italy, Netherlands, Greece, Germany, U.K., Croatia, Spain, France, Norway, Poland, Russian Federation, Romania, Hungary, Slovakia, Canada
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.